The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations
Magnetic resonance imaging (MRI) can detect disease recurrence after focal therapy for prostate cancer, but there is no robust guidance regarding its use. The TARGET consensus recommendations provide guidance on the acquisition, interpretation, and reporting of MRI after focal therapy, as well as mi...
Gespeichert in:
| Veröffentlicht in: | European urology 2024-05, Vol.85 (5), p.466-482 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 482 |
|---|---|
| container_issue | 5 |
| container_start_page | 466 |
| container_title | European urology |
| container_volume | 85 |
| creator | Light, Alexander Mayor, Nikhil Cullen, Emma Kirkham, Alex Padhani, Anwar R. Arya, Manit Bomers, Joyce G.R. Dudderidge, Tim Ehdaie, Behfar Freeman, Alex Guillaumier, Stephanie Hindley, Richard Lakhani, Amish Pendse, Douglas Punwani, Shonit Rastinehad, Ardeshir R. Rouvière, Olivier Sanchez-Salas, Rafael Schoots, Ivo G. Sokhi, Heminder K. Tam, Henry Tempany, Clare M. Valerio, Massimo Verma, Sadhna Villeirs, Geert van der Meulen, Jan Ahmed, Hashim U. Shah, Taimur T. |
| description | Magnetic resonance imaging (MRI) can detect disease recurrence after focal therapy for prostate cancer, but there is no robust guidance regarding its use. The TARGET consensus recommendations provide guidance on the acquisition, interpretation, and reporting of MRI after focal therapy, as well as minimum standards for study reporting.
Magnetic resonance imaging (MRI) can detect recurrences after focal therapy for prostate cancer but there is no robust guidance regarding its use. Our objective was to produce consensus recommendations on MRI acquisition, interpretation, and reporting after focal therapy.
A systematic review was performed in July 2022 to develop consensus statements. A two-round consensus exercise was then performed, with a consensus meeting in January 2023, during which 329 statements were scored by 23 panellists from Europe and North America spanning urology, radiology, and pathology with experience across eight focal therapy modalities. Using RAND Corporation/University of California-Los Angeles methodology, the Transatlantic Recommendations for Prostate Gland Evaluation with MRI after Focal Therapy (TARGET) were based on consensus for statements scored with agreement or disagreement.
In total, 73 studies were included in the review. All 20 studies (100%) reporting suspicious imaging features cited focal contrast enhancement as suspicious for cancer recurrence. Of 31 studies reporting MRI assessment criteria, the Prostate Imaging-Reporting and Data System (PI-RADS) score was the scheme used most often (20 studies; 65%), followed by a 5-point Likert score (six studies; 19%). For the consensus exercise, consensus for statements scored with agreement or disagreement increased from 227 of 295 statements (76.9%) in round one to 270 of 329 statements (82.1%) in round two. Key recommendations include performing routine MRI at 12 mo using a multiparametric protocol compliant with PI-RADS version 2.1 standards. PI-RADS category scores for assessing recurrence within the ablation zone should be avoided. An alternative 5-point scoring system is presented that includes a major dynamic contrast enhancement (DCE) sequence and joint minor diffusion-weighted imaging and T2-weighted sequences. For the DCE sequence, focal nodular strong early enhancement was the most suspicious imaging finding. A structured minimum reporting data set and minimum reporting standards for studies detailing MRI data after focal therapy are presented.
The TARGET consensus recomm |
| doi_str_mv | 10.1016/j.eururo.2024.02.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2974003787</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0302283824000678</els_id><sourcerecordid>2974003787</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-6d3c5871de69f1ebdb58e80f80d42835c84ccfb66c17fc77a8d8b7e0d99aac053</originalsourceid><addsrcrecordid>eNp9kc1uEzEUhS0EoiHwBgh5WRYz2PPrYYEURWkaqQhUhrXlse-kjmbsYHta5eF4N5xOy4IFq7u45_hcfweh95SklNDq0yGFyU3OphnJipRkKSH0BVpQVudJXVbkJVqQnGRJxnJ2gd54fyCE5GWTv0YXOStpkzGyQL_bO8CtE8aLMAgTtMS3IO04glEiaGs87q3D3531QQTA2yhSeHMvhulxjR90uMNfxd7A7PXWCCMB70ax12aPV30Ah6-sFAOOWU4cT_iyXd1uN-3Hz3iFf5x8gFHM5nsND_gcsDPRZR4Tom8dzwDjJ__vbW_Rq14MHt49zSX6ebVp19fJzbftbr26SWRBWEgqlcuS1VRB1fQUOtWVDBjpGVFFxFNKVkjZd1Ulad3LuhZMsa4GoppGCEnKfIku53ePzv6awAc-ai9hiDDATp5nTV1EuHVkv0TFLJURmXfQ86PTo3AnTgk_F8cPfC6On4vjJOOxuGj78JQwdSOov6bnpqLgyyyA-M_IyXEvNUTSSjuQgSur_5_wB_wbsEQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2974003787</pqid></control><display><type>article</type><title>The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Light, Alexander ; Mayor, Nikhil ; Cullen, Emma ; Kirkham, Alex ; Padhani, Anwar R. ; Arya, Manit ; Bomers, Joyce G.R. ; Dudderidge, Tim ; Ehdaie, Behfar ; Freeman, Alex ; Guillaumier, Stephanie ; Hindley, Richard ; Lakhani, Amish ; Pendse, Douglas ; Punwani, Shonit ; Rastinehad, Ardeshir R. ; Rouvière, Olivier ; Sanchez-Salas, Rafael ; Schoots, Ivo G. ; Sokhi, Heminder K. ; Tam, Henry ; Tempany, Clare M. ; Valerio, Massimo ; Verma, Sadhna ; Villeirs, Geert ; van der Meulen, Jan ; Ahmed, Hashim U. ; Shah, Taimur T.</creator><creatorcontrib>Light, Alexander ; Mayor, Nikhil ; Cullen, Emma ; Kirkham, Alex ; Padhani, Anwar R. ; Arya, Manit ; Bomers, Joyce G.R. ; Dudderidge, Tim ; Ehdaie, Behfar ; Freeman, Alex ; Guillaumier, Stephanie ; Hindley, Richard ; Lakhani, Amish ; Pendse, Douglas ; Punwani, Shonit ; Rastinehad, Ardeshir R. ; Rouvière, Olivier ; Sanchez-Salas, Rafael ; Schoots, Ivo G. ; Sokhi, Heminder K. ; Tam, Henry ; Tempany, Clare M. ; Valerio, Massimo ; Verma, Sadhna ; Villeirs, Geert ; van der Meulen, Jan ; Ahmed, Hashim U. ; Shah, Taimur T.</creatorcontrib><description>Magnetic resonance imaging (MRI) can detect disease recurrence after focal therapy for prostate cancer, but there is no robust guidance regarding its use. The TARGET consensus recommendations provide guidance on the acquisition, interpretation, and reporting of MRI after focal therapy, as well as minimum standards for study reporting.
Magnetic resonance imaging (MRI) can detect recurrences after focal therapy for prostate cancer but there is no robust guidance regarding its use. Our objective was to produce consensus recommendations on MRI acquisition, interpretation, and reporting after focal therapy.
A systematic review was performed in July 2022 to develop consensus statements. A two-round consensus exercise was then performed, with a consensus meeting in January 2023, during which 329 statements were scored by 23 panellists from Europe and North America spanning urology, radiology, and pathology with experience across eight focal therapy modalities. Using RAND Corporation/University of California-Los Angeles methodology, the Transatlantic Recommendations for Prostate Gland Evaluation with MRI after Focal Therapy (TARGET) were based on consensus for statements scored with agreement or disagreement.
In total, 73 studies were included in the review. All 20 studies (100%) reporting suspicious imaging features cited focal contrast enhancement as suspicious for cancer recurrence. Of 31 studies reporting MRI assessment criteria, the Prostate Imaging-Reporting and Data System (PI-RADS) score was the scheme used most often (20 studies; 65%), followed by a 5-point Likert score (six studies; 19%). For the consensus exercise, consensus for statements scored with agreement or disagreement increased from 227 of 295 statements (76.9%) in round one to 270 of 329 statements (82.1%) in round two. Key recommendations include performing routine MRI at 12 mo using a multiparametric protocol compliant with PI-RADS version 2.1 standards. PI-RADS category scores for assessing recurrence within the ablation zone should be avoided. An alternative 5-point scoring system is presented that includes a major dynamic contrast enhancement (DCE) sequence and joint minor diffusion-weighted imaging and T2-weighted sequences. For the DCE sequence, focal nodular strong early enhancement was the most suspicious imaging finding. A structured minimum reporting data set and minimum reporting standards for studies detailing MRI data after focal therapy are presented.
The TARGET consensus recommendations may improve MRI acquisition, interpretation, and reporting after focal therapy for prostate cancer and provide minimum standards for study reporting.
Magnetic resonance imaging (MRI) scans can detect recurrent of prostate cancer after focal treatments, but there is a lack of guidance on MRI use for this purpose. We report new expert recommendations that may improve practice.</description><identifier>ISSN: 0302-2838</identifier><identifier>ISSN: 1873-7560</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2024.02.001</identifier><identifier>PMID: 38519280</identifier><language>eng</language><publisher>Switzerland: Elsevier B.V</publisher><subject>Ablation ; Consensus ; Cryotherapy ; Diffusion Magnetic Resonance Imaging ; Focal therapy ; High-intensity focused ultrasound ; Humans ; In-field recurrence ; Magnetic resonance imaging ; Magnetic Resonance Imaging - methods ; Male ; Multiparametric ; Neoplasm Recurrence, Local - diagnostic imaging ; Neoplasm Recurrence, Local - pathology ; Prostate - diagnostic imaging ; Prostate - pathology ; Prostate cancer ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - therapy ; Recurrence</subject><ispartof>European urology, 2024-05, Vol.85 (5), p.466-482</ispartof><rights>2024 The Author(s)</rights><rights>Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-6d3c5871de69f1ebdb58e80f80d42835c84ccfb66c17fc77a8d8b7e0d99aac053</citedby><cites>FETCH-LOGICAL-c408t-6d3c5871de69f1ebdb58e80f80d42835c84ccfb66c17fc77a8d8b7e0d99aac053</cites><orcidid>0000-0001-7246-3651</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.eururo.2024.02.001$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38519280$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Light, Alexander</creatorcontrib><creatorcontrib>Mayor, Nikhil</creatorcontrib><creatorcontrib>Cullen, Emma</creatorcontrib><creatorcontrib>Kirkham, Alex</creatorcontrib><creatorcontrib>Padhani, Anwar R.</creatorcontrib><creatorcontrib>Arya, Manit</creatorcontrib><creatorcontrib>Bomers, Joyce G.R.</creatorcontrib><creatorcontrib>Dudderidge, Tim</creatorcontrib><creatorcontrib>Ehdaie, Behfar</creatorcontrib><creatorcontrib>Freeman, Alex</creatorcontrib><creatorcontrib>Guillaumier, Stephanie</creatorcontrib><creatorcontrib>Hindley, Richard</creatorcontrib><creatorcontrib>Lakhani, Amish</creatorcontrib><creatorcontrib>Pendse, Douglas</creatorcontrib><creatorcontrib>Punwani, Shonit</creatorcontrib><creatorcontrib>Rastinehad, Ardeshir R.</creatorcontrib><creatorcontrib>Rouvière, Olivier</creatorcontrib><creatorcontrib>Sanchez-Salas, Rafael</creatorcontrib><creatorcontrib>Schoots, Ivo G.</creatorcontrib><creatorcontrib>Sokhi, Heminder K.</creatorcontrib><creatorcontrib>Tam, Henry</creatorcontrib><creatorcontrib>Tempany, Clare M.</creatorcontrib><creatorcontrib>Valerio, Massimo</creatorcontrib><creatorcontrib>Verma, Sadhna</creatorcontrib><creatorcontrib>Villeirs, Geert</creatorcontrib><creatorcontrib>van der Meulen, Jan</creatorcontrib><creatorcontrib>Ahmed, Hashim U.</creatorcontrib><creatorcontrib>Shah, Taimur T.</creatorcontrib><title>The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>Magnetic resonance imaging (MRI) can detect disease recurrence after focal therapy for prostate cancer, but there is no robust guidance regarding its use. The TARGET consensus recommendations provide guidance on the acquisition, interpretation, and reporting of MRI after focal therapy, as well as minimum standards for study reporting.
Magnetic resonance imaging (MRI) can detect recurrences after focal therapy for prostate cancer but there is no robust guidance regarding its use. Our objective was to produce consensus recommendations on MRI acquisition, interpretation, and reporting after focal therapy.
A systematic review was performed in July 2022 to develop consensus statements. A two-round consensus exercise was then performed, with a consensus meeting in January 2023, during which 329 statements were scored by 23 panellists from Europe and North America spanning urology, radiology, and pathology with experience across eight focal therapy modalities. Using RAND Corporation/University of California-Los Angeles methodology, the Transatlantic Recommendations for Prostate Gland Evaluation with MRI after Focal Therapy (TARGET) were based on consensus for statements scored with agreement or disagreement.
In total, 73 studies were included in the review. All 20 studies (100%) reporting suspicious imaging features cited focal contrast enhancement as suspicious for cancer recurrence. Of 31 studies reporting MRI assessment criteria, the Prostate Imaging-Reporting and Data System (PI-RADS) score was the scheme used most often (20 studies; 65%), followed by a 5-point Likert score (six studies; 19%). For the consensus exercise, consensus for statements scored with agreement or disagreement increased from 227 of 295 statements (76.9%) in round one to 270 of 329 statements (82.1%) in round two. Key recommendations include performing routine MRI at 12 mo using a multiparametric protocol compliant with PI-RADS version 2.1 standards. PI-RADS category scores for assessing recurrence within the ablation zone should be avoided. An alternative 5-point scoring system is presented that includes a major dynamic contrast enhancement (DCE) sequence and joint minor diffusion-weighted imaging and T2-weighted sequences. For the DCE sequence, focal nodular strong early enhancement was the most suspicious imaging finding. A structured minimum reporting data set and minimum reporting standards for studies detailing MRI data after focal therapy are presented.
The TARGET consensus recommendations may improve MRI acquisition, interpretation, and reporting after focal therapy for prostate cancer and provide minimum standards for study reporting.
Magnetic resonance imaging (MRI) scans can detect recurrent of prostate cancer after focal treatments, but there is a lack of guidance on MRI use for this purpose. We report new expert recommendations that may improve practice.</description><subject>Ablation</subject><subject>Consensus</subject><subject>Cryotherapy</subject><subject>Diffusion Magnetic Resonance Imaging</subject><subject>Focal therapy</subject><subject>High-intensity focused ultrasound</subject><subject>Humans</subject><subject>In-field recurrence</subject><subject>Magnetic resonance imaging</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Male</subject><subject>Multiparametric</subject><subject>Neoplasm Recurrence, Local - diagnostic imaging</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Prostate - diagnostic imaging</subject><subject>Prostate - pathology</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Recurrence</subject><issn>0302-2838</issn><issn>1873-7560</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1uEzEUhS0EoiHwBgh5WRYz2PPrYYEURWkaqQhUhrXlse-kjmbsYHta5eF4N5xOy4IFq7u45_hcfweh95SklNDq0yGFyU3OphnJipRkKSH0BVpQVudJXVbkJVqQnGRJxnJ2gd54fyCE5GWTv0YXOStpkzGyQL_bO8CtE8aLMAgTtMS3IO04glEiaGs87q3D3531QQTA2yhSeHMvhulxjR90uMNfxd7A7PXWCCMB70ax12aPV30Ah6-sFAOOWU4cT_iyXd1uN-3Hz3iFf5x8gFHM5nsND_gcsDPRZR4Tom8dzwDjJ__vbW_Rq14MHt49zSX6ebVp19fJzbftbr26SWRBWEgqlcuS1VRB1fQUOtWVDBjpGVFFxFNKVkjZd1Ulad3LuhZMsa4GoppGCEnKfIku53ePzv6awAc-ai9hiDDATp5nTV1EuHVkv0TFLJURmXfQ86PTo3AnTgk_F8cPfC6On4vjJOOxuGj78JQwdSOov6bnpqLgyyyA-M_IyXEvNUTSSjuQgSur_5_wB_wbsEQ</recordid><startdate>202405</startdate><enddate>202405</enddate><creator>Light, Alexander</creator><creator>Mayor, Nikhil</creator><creator>Cullen, Emma</creator><creator>Kirkham, Alex</creator><creator>Padhani, Anwar R.</creator><creator>Arya, Manit</creator><creator>Bomers, Joyce G.R.</creator><creator>Dudderidge, Tim</creator><creator>Ehdaie, Behfar</creator><creator>Freeman, Alex</creator><creator>Guillaumier, Stephanie</creator><creator>Hindley, Richard</creator><creator>Lakhani, Amish</creator><creator>Pendse, Douglas</creator><creator>Punwani, Shonit</creator><creator>Rastinehad, Ardeshir R.</creator><creator>Rouvière, Olivier</creator><creator>Sanchez-Salas, Rafael</creator><creator>Schoots, Ivo G.</creator><creator>Sokhi, Heminder K.</creator><creator>Tam, Henry</creator><creator>Tempany, Clare M.</creator><creator>Valerio, Massimo</creator><creator>Verma, Sadhna</creator><creator>Villeirs, Geert</creator><creator>van der Meulen, Jan</creator><creator>Ahmed, Hashim U.</creator><creator>Shah, Taimur T.</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7246-3651</orcidid></search><sort><creationdate>202405</creationdate><title>The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations</title><author>Light, Alexander ; Mayor, Nikhil ; Cullen, Emma ; Kirkham, Alex ; Padhani, Anwar R. ; Arya, Manit ; Bomers, Joyce G.R. ; Dudderidge, Tim ; Ehdaie, Behfar ; Freeman, Alex ; Guillaumier, Stephanie ; Hindley, Richard ; Lakhani, Amish ; Pendse, Douglas ; Punwani, Shonit ; Rastinehad, Ardeshir R. ; Rouvière, Olivier ; Sanchez-Salas, Rafael ; Schoots, Ivo G. ; Sokhi, Heminder K. ; Tam, Henry ; Tempany, Clare M. ; Valerio, Massimo ; Verma, Sadhna ; Villeirs, Geert ; van der Meulen, Jan ; Ahmed, Hashim U. ; Shah, Taimur T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-6d3c5871de69f1ebdb58e80f80d42835c84ccfb66c17fc77a8d8b7e0d99aac053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Ablation</topic><topic>Consensus</topic><topic>Cryotherapy</topic><topic>Diffusion Magnetic Resonance Imaging</topic><topic>Focal therapy</topic><topic>High-intensity focused ultrasound</topic><topic>Humans</topic><topic>In-field recurrence</topic><topic>Magnetic resonance imaging</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Male</topic><topic>Multiparametric</topic><topic>Neoplasm Recurrence, Local - diagnostic imaging</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Prostate - diagnostic imaging</topic><topic>Prostate - pathology</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Recurrence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Light, Alexander</creatorcontrib><creatorcontrib>Mayor, Nikhil</creatorcontrib><creatorcontrib>Cullen, Emma</creatorcontrib><creatorcontrib>Kirkham, Alex</creatorcontrib><creatorcontrib>Padhani, Anwar R.</creatorcontrib><creatorcontrib>Arya, Manit</creatorcontrib><creatorcontrib>Bomers, Joyce G.R.</creatorcontrib><creatorcontrib>Dudderidge, Tim</creatorcontrib><creatorcontrib>Ehdaie, Behfar</creatorcontrib><creatorcontrib>Freeman, Alex</creatorcontrib><creatorcontrib>Guillaumier, Stephanie</creatorcontrib><creatorcontrib>Hindley, Richard</creatorcontrib><creatorcontrib>Lakhani, Amish</creatorcontrib><creatorcontrib>Pendse, Douglas</creatorcontrib><creatorcontrib>Punwani, Shonit</creatorcontrib><creatorcontrib>Rastinehad, Ardeshir R.</creatorcontrib><creatorcontrib>Rouvière, Olivier</creatorcontrib><creatorcontrib>Sanchez-Salas, Rafael</creatorcontrib><creatorcontrib>Schoots, Ivo G.</creatorcontrib><creatorcontrib>Sokhi, Heminder K.</creatorcontrib><creatorcontrib>Tam, Henry</creatorcontrib><creatorcontrib>Tempany, Clare M.</creatorcontrib><creatorcontrib>Valerio, Massimo</creatorcontrib><creatorcontrib>Verma, Sadhna</creatorcontrib><creatorcontrib>Villeirs, Geert</creatorcontrib><creatorcontrib>van der Meulen, Jan</creatorcontrib><creatorcontrib>Ahmed, Hashim U.</creatorcontrib><creatorcontrib>Shah, Taimur T.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Light, Alexander</au><au>Mayor, Nikhil</au><au>Cullen, Emma</au><au>Kirkham, Alex</au><au>Padhani, Anwar R.</au><au>Arya, Manit</au><au>Bomers, Joyce G.R.</au><au>Dudderidge, Tim</au><au>Ehdaie, Behfar</au><au>Freeman, Alex</au><au>Guillaumier, Stephanie</au><au>Hindley, Richard</au><au>Lakhani, Amish</au><au>Pendse, Douglas</au><au>Punwani, Shonit</au><au>Rastinehad, Ardeshir R.</au><au>Rouvière, Olivier</au><au>Sanchez-Salas, Rafael</au><au>Schoots, Ivo G.</au><au>Sokhi, Heminder K.</au><au>Tam, Henry</au><au>Tempany, Clare M.</au><au>Valerio, Massimo</au><au>Verma, Sadhna</au><au>Villeirs, Geert</au><au>van der Meulen, Jan</au><au>Ahmed, Hashim U.</au><au>Shah, Taimur T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2024-05</date><risdate>2024</risdate><volume>85</volume><issue>5</issue><spage>466</spage><epage>482</epage><pages>466-482</pages><issn>0302-2838</issn><issn>1873-7560</issn><eissn>1873-7560</eissn><abstract>Magnetic resonance imaging (MRI) can detect disease recurrence after focal therapy for prostate cancer, but there is no robust guidance regarding its use. The TARGET consensus recommendations provide guidance on the acquisition, interpretation, and reporting of MRI after focal therapy, as well as minimum standards for study reporting.
Magnetic resonance imaging (MRI) can detect recurrences after focal therapy for prostate cancer but there is no robust guidance regarding its use. Our objective was to produce consensus recommendations on MRI acquisition, interpretation, and reporting after focal therapy.
A systematic review was performed in July 2022 to develop consensus statements. A two-round consensus exercise was then performed, with a consensus meeting in January 2023, during which 329 statements were scored by 23 panellists from Europe and North America spanning urology, radiology, and pathology with experience across eight focal therapy modalities. Using RAND Corporation/University of California-Los Angeles methodology, the Transatlantic Recommendations for Prostate Gland Evaluation with MRI after Focal Therapy (TARGET) were based on consensus for statements scored with agreement or disagreement.
In total, 73 studies were included in the review. All 20 studies (100%) reporting suspicious imaging features cited focal contrast enhancement as suspicious for cancer recurrence. Of 31 studies reporting MRI assessment criteria, the Prostate Imaging-Reporting and Data System (PI-RADS) score was the scheme used most often (20 studies; 65%), followed by a 5-point Likert score (six studies; 19%). For the consensus exercise, consensus for statements scored with agreement or disagreement increased from 227 of 295 statements (76.9%) in round one to 270 of 329 statements (82.1%) in round two. Key recommendations include performing routine MRI at 12 mo using a multiparametric protocol compliant with PI-RADS version 2.1 standards. PI-RADS category scores for assessing recurrence within the ablation zone should be avoided. An alternative 5-point scoring system is presented that includes a major dynamic contrast enhancement (DCE) sequence and joint minor diffusion-weighted imaging and T2-weighted sequences. For the DCE sequence, focal nodular strong early enhancement was the most suspicious imaging finding. A structured minimum reporting data set and minimum reporting standards for studies detailing MRI data after focal therapy are presented.
The TARGET consensus recommendations may improve MRI acquisition, interpretation, and reporting after focal therapy for prostate cancer and provide minimum standards for study reporting.
Magnetic resonance imaging (MRI) scans can detect recurrent of prostate cancer after focal treatments, but there is a lack of guidance on MRI use for this purpose. We report new expert recommendations that may improve practice.</abstract><cop>Switzerland</cop><pub>Elsevier B.V</pub><pmid>38519280</pmid><doi>10.1016/j.eururo.2024.02.001</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0001-7246-3651</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0302-2838 |
| ispartof | European urology, 2024-05, Vol.85 (5), p.466-482 |
| issn | 0302-2838 1873-7560 1873-7560 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2974003787 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Ablation Consensus Cryotherapy Diffusion Magnetic Resonance Imaging Focal therapy High-intensity focused ultrasound Humans In-field recurrence Magnetic resonance imaging Magnetic Resonance Imaging - methods Male Multiparametric Neoplasm Recurrence, Local - diagnostic imaging Neoplasm Recurrence, Local - pathology Prostate - diagnostic imaging Prostate - pathology Prostate cancer Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - therapy Recurrence |
| title | The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T04%3A17%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Transatlantic%20Recommendations%20for%20Prostate%20Gland%20Evaluation%20with%20Magnetic%20Resonance%20Imaging%20After%20Focal%20Therapy%20(TARGET):%20A%20Systematic%20Review%20and%20International%20Consensus%20Recommendations&rft.jtitle=European%20urology&rft.au=Light,%20Alexander&rft.date=2024-05&rft.volume=85&rft.issue=5&rft.spage=466&rft.epage=482&rft.pages=466-482&rft.issn=0302-2838&rft.eissn=1873-7560&rft_id=info:doi/10.1016/j.eururo.2024.02.001&rft_dat=%3Cproquest_cross%3E2974003787%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2974003787&rft_id=info:pmid/38519280&rft_els_id=S0302283824000678&rfr_iscdi=true |